Biotech Daily Home
|
Biotech Daily covers the major announcements from more than 140 ASX-listed biotech companies as well as the major research institutes and developments in government policy. Published shortly after the stock market closes five days a week - excluding public holidays - Biotech Daily is the only comprehensive daily source of information on the listed biotech sector. The Biotech Daily Top 40 Index (BDI-40) is selected on the basis of interesting technologies, benefit to human health and investment potential. Market capitalization is important, but is not a sole arbiter. Base-rate subscriptions are $A1500 a year (including GST in Australia). Subscribers include biotech directors and CEOs, major pharmaceutical companies, universities, research institutes, investment houses, market analysts, retail investors, doctors, medical specialists and hospital management.
|
|
All The Dope On Medicine, Marijuana, Cannabis & Hemp FDA Okays Redhill Talicia (Sydney's Heliconda) For H. Pylori Dr Boreham's Crucible: Avita Medical
Botanix Falls 48% As Cannabinoid BTX1503 Misses Acne Endpoint Clinuvel Up 63% On FDA Scenesse For EPP Approval Antisense Jumps 100% On ATL1102 'Positive Drug Effect For DMD'
2019: BDI-40 Up 118%, ASX200 18%, Big Caps 46% Avita Up 919%, Orthocell 543%, Painchek 497%, Opthea 453%, Alcidion 408%
January 1, 2020 Despite a slight December downturn, the Biotech Daily Top-40 Index (BDI-40) closed the year up 117.8 percent to a collective market capitalization of $14,839 million.
The benchmark S&P ASX200 improved 18.4 percent for the year, while the Nasdaq Biotechnology Index (NBI) was up 24.4 percent, and the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed a further 45.5 percent.
CSL climbed 49.2 percent to close the year at $125,160 million, Resmed rose 38.8 percent to $31,485 million, with Cochlear up 29.7 percent to $12,996 million.
Avita stole the show, climbing 919.4 percent from $134 million at the end of December 2018 to $1,366 million at December 31, 2019.
Fourteen of the BDI-40 stocks climbed 100 percent or more during the year, with Medical Developments and Mesoblast only improving 99.3 percent and 93.4 percent, respectively.
Other big-hitters in the BDI-20 included Paradigm up 292.5 percent to $802 million, followed by Polynovo up 231.3 percent to $1,302 million, Telix up 176.8 percent to $393 million, Pro Medicus up 106.1 percent to $2,323 million, Volpara up 102.5 percent to $399 million and Compumedics only improving 100 percent to $142 million.
The second biggest biotech increase was in the Second 20, with Orthocell improving 542.9 percent from a very low base to $90 million, followed by Painchek, which is currently outside the Top 40 but banging hard on the door, up 497.0 percent to $197 million.
Opthea was up 453.1 percent to $802 million, Alcidion – also currently outside the Top 40 – was up 408.3 percent to $183 million, with Antisense up 380.0 percent to $38 million. Other notables included Memphasys (370.0%), Total Brain (344.44%) and Mach7 (309.7%), with Pharmaust, Recce and Resonance all up 300 percent.
Cannabis Corner eased a further 5.95 percent in December to a collective market capitalization of $869 million, down 26.1 percent for the year and 54.6 percent from the July 31 high of $1,913 million.
On the Nasdaq, Israel’s Redhill with Australian assets was up 51.2 percent for the year to $304 million, Queensland’s Protagonist improved 18.2 percent to $273 million and Eyepoint (formerly Psivida) slipped 6.3 percent to $238 million.
BDI-40 v S&P ASX200 Jun 30, 2006 to Dec 31, 2019
 3-Year Big Caps (Cochlear, CSL, Resmed) to Dec 31, 2019
 BDI-40 ($m) v S&P ASX200 – Year to Dec 31, 2019
(current, raw data) 
|
Click here for Biotech Daily's archive
Biotech Daily Top 40 With Market Capitalization At Dec 31, 2019
* Biotech Daily editor, David Langsam, owns shares in Acrux, Alterity, Amplia, Cynata, Mesoblast
Nanosonics, Neuren, Patrys, Polynovo, Telix and Volpara, as well as non-biotechnology stocks.
Through Australian Ethical Superannuation he has an indirect interest in a range of biotechnology companies.
These holdings are liable to change: http://www.australianethical.com.au/who-we-invest-in.